BioLife Solutions (NasdaqCM:BLFS) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAnna Snopkowski - Equity Research AssociateRoderick de Greef - Chairman and CEOTroy Wichterman - CFOConference Call ParticipantsBrendan Smith - Director, Life Science & Diagnostic Tools and Biotech AnalystCarl Byrnes - Managing Director, Senior Research AnalystMacae Etoch - Equity Research AnalystMatt Hewett - Senior Research AnalystMatt Stanton - Equity Research AnalystMichael Okunewitch - Senior Resea ...

BioLife Solutions (NasdaqCM:BLFS) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAnna Snopkowski - Equity Research AssociateRoderick de Greef - Chairman and CEOTroy Wichterman - CFOConference Call ParticipantsBrendan Smith - Director, Life Science & Diagnostic Tools and Biotech AnalystCarl Byrnes - Managing Director, Senior Research AnalystMacason Etok - Equity Research AnalystMatt Hewitt - Senior Research AnalystMatt Stanton - Equity Research AnalystMichael Okunewitch - Senior Rese ...

BioLife Solutions (NasdaqCM:BLFS) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker7Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Q4 2025 Shareholder and Analyst Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. I would now like to turn the call over to Troy Wichterman, Chief Financial Officer of BioLife Solutions. Please go ahead.Speaker9Tha ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporat ...

Financial Performance - BioLife Solutions, Inc. announced preliminary unaudited revenue for Q4 2025 and the full year ended December 31, 2025[4]. - The report does not provide specific revenue figures or growth percentages in the available content[4]. Compliance and Reporting - The report was filed on January 12, 2026, indicating the company's compliance with the Securities Exchange Act of 1934[4]. - The company has not elected to use the extended transition period for complying with new financial accounting standards[3]. - The financial results will not be deemed "filed" under the Exchange Act, limiting liability under Section 18[5]. - The Chief Financial Officer, Troy Wichterman, signed the report, indicating executive oversight[10]. Company Information - The company is listed on the Nasdaq Stock Market under the trading symbol BLFS[2]. - The company operates from its headquarters located at 3303 Monte Villa Parkway, Bothell, WA[2]. Additional Information - The press release detailing the financial results is attached as Exhibit 99.1[6]. - No information on new products, technologies, market expansion, or mergers and acquisitions was provided in the current report[4].

Core Viewpoint - BioLife Solutions, Inc. is set to release its fourth quarter and full year 2025 financial results on February 26, 2026, along with a business update [1] Company Overview - BioLife Solutions is a leading developer and supplier of bioproduction products and services specifically for the cell and gene therapy (CGT) market [1] - The company provides solutions that maintain the health and function of biologic materials during various stages including collection, development, storage, and distribution [1] Financial Reporting - The financial results will be discussed in a conference call and live webcast scheduled for 4:30 PM ET (1:30 PM PT) on the release date [1] - Access to the webcast will be available through the Investor Relations page of the BioLife Solutions website [1] Contact Information - The Chief Financial Officer, Troy Wichterman, can be contacted for media and investor relations inquiries [1]

BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market [Accessibility Statement] Skip NavigationBOTHELL, Wash., Feb. 12, 2026 /PRNewswire/ -- [BioLife Solutions, Inc.](NASDAQ: [BLFS]), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces it has entered into a multi-year supply agreement with Qkine Limited under which BioLife will distribute certain c ...

Industry Overview - The Zacks Medical - Products industry is facing challenges due to tariffs imposed by the U.S. on trading partners, impacting margins for companies like GE HealthCare, Baxter, and Abbott [1] - Medical device makers are experiencing rising commodity and manufacturing costs post-COVID-19, particularly in consumer-facing areas like Nutrition, leading to price hikes that may constrain volume due to increased price sensitivity among consumers [2] - The industry's profitability is under strain from tariff-related expenses and persistent component shortages, which create inefficiencies and constrain output [7] Trends and Innovations - Industry players are mitigating challenges through product innovation and the adoption of AI and digital services, with the rise of GLP-1 medication acting as a tailwind for certain medical device areas [3] - The market for remote patient monitoring platforms is projected to reach $57 billion by 2030, driving margin expansion and shifting profit pools from hardware to data-driven services [9] - The U.S. market is shifting from inpatient hospital settings to Ambulatory Surgery Centers (ASCs) and home-based monitoring, with the ASC market expected to reach $205 billion by 2030 [10] Company Performance - Boston Scientific (BSX) is positioned for strong growth driven by demand across its diversified product portfolio, with a commitment to over 10% growth over the next three years [29] - ResMed is experiencing strong momentum with 11% top-line growth in Q2 fiscal 2026, driven by rising demand for CPAP therapy and the adoption of GLP-1 drugs [35][36] - Phibro Animal Health Corporation (PAHC) is benefiting from the integration of the Zoetis Medicated Feed Additive portfolio, contributing $80.5 million in sales in Q1 fiscal 2026, and expects favorable net price impacts to improve profitability [42] Financial Outlook - The Zacks Consensus Estimate for BioLife Solutions (BLFS) indicates a 16.4% revenue growth for 2026, with earnings expected to grow by 38.1% [27] - Boston Scientific's revenue for 2026 is estimated at $22.32 billion, projecting an 11.3% growth, with EPS expected to improve by 13.5% [32] - ResMed's revenue for fiscal 2026 is pegged at $5.58 billion, indicating an 8.5% growth, with EPS expected to rise by 15% [39] - PAHC's revenue for fiscal 2026 is estimated at $1.47 billion, projecting a 13.1% growth, with EPS expected to improve by 32.1% [46]

Core Insights - BioLife Solutions reported a preliminary fourth quarter revenue of $24.8 million, marking a 20% increase from $20.7 million in the same quarter of the previous year [1][7] - For the full year 2025, the company achieved revenue of $96.2 million, which is a 29% increase from $74.6 million in 2024, exceeding the previously raised guidance range [1][7] Financial Performance - The fourth quarter revenue growth was primarily driven by the biopreservation product line [2] - The company’s revenue from continuing operations for 2025 surpassed the high end of the guidance range of $95.0 million to $96.0 million, adjusted for the divestiture of the evo business [7] Strategic Positioning - Following the divestiture of the evo product line, BioLife is positioned as a pure-play cell processing company, focusing on high-value, recurring revenue franchises [2] - The company anticipates revenue growth across its product portfolio in 2026, along with an expansion of adjusted EBITDA margin due to increased operating leverage [3]

Core Insights - BioLife Solutions, a provider of bioproduction tools for cell and gene therapy, reported a significant insider sale by its CFO, Troy Wichterman, who sold 30,000 shares for approximately $771,600 amid a modestly declining share price [2][9]. Transaction Summary - The CFO sold 30,000 shares at a weighted average price of $25.72, resulting in a transaction value of about $771,600 [3]. - Post-transaction, Wichterman holds 152,769 shares, which is approximately 60.5% of his holdings at the start of the reporting period [4]. - This sale represents 16.4% of his direct ownership [4]. Company Overview - As of December 4, 2025, BioLife Solutions has a market capitalization of $1.19 billion and reported a revenue of $100.1 million for the trailing twelve months [5]. - The company's stock price has decreased by 2.1% over the past year [5]. Recent Performance - In early November, BioLife Solutions reported a 31.2% increase in revenue to $28.1 million for the third quarter, with the operating loss narrowing from $418,000 to $89,000 [10]. - Despite the revenue growth, the stock has declined by 5.5% over the past year, underperforming compared to the S&P 500 and Nasdaq Composite, which returned 15.6% and 20.2%, respectively [10]. Company Profile - BioLife Solutions specializes in bioproduction tools and services for the cell and gene therapy sector, utilizing proprietary preservation and logistics technologies [8]. - The company serves biotechnology and pharmaceutical companies, academic research institutions, and commercial manufacturers of biologic-based therapies across various international markets [14].